A clinical trial update for carbetocin was recorded on October 15, 2026. The study, registered as NCT06173531 and titled "Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome," is a Phase 3 trial.
Its status is listed as completed as of this update. The trial examined a nasal spray formulation of carbetocin in people with Prader-Willi syndrome, focused on hyperphagia.
Carbetocin remains classified as unapproved for this research use. No results, outcomes, or efficacy data are included in this status update. Completion of a trial reflects the conclusion of the study procedures as registered, not a determination of safety or benefit.
Readers should consult the official registry entry for details on the trial design, enrollment, and any future posting of results. For additional context on carbetocin, see the compound overview.